



Domain	Influenza Immune Modulation
DSA version and date	V1.1 dated 29 September 2023

Summary

In this domain of the REMAP-CAP trial, participants meeting the platform entry criteria with microbiological testing-confirmed influenza virus infection will be randomized to receive one of up to three interventions depending on availability and acceptability:

- No immune modulation (no placebo)
- Tocilizumab
- Baricitinib

Region specific participation

Patients who are known or suspected of being pregnant will be **excluded** from the tocilizumab intervention

Domain	Strata	State	Intervention	Site will participate in
Influenza Immune Modulation (N)	PINSNP	Moderate	Not available	Not available
		Severe	No immune modulation	<input type="checkbox"/>
			Tocilizumab	<input type="checkbox"/>
	PISOP	Moderate	Not available	Not available
		Severe	Not available	Not available
				Baricitinib

Name site:

Name PI:

Date:

Signature: